Inhibitors targeting KIFC1 have been developed, showing efficacy in blocking tumor growth and metastasis,[55, 56, 57, 58] as well as enhancing sensitivity to therapeutic agents.[22, 25, 26] In our study, the KIFC1 inhibitor AZ82 markedly inhibited the growth of STS both in vivo and in vitro, while concurrently promoting senescence. This evidence concerns the gene KIFC1 and telomere syndrome.